Arthritis interception with Guselkumab in subclinical psoriatic arthritis patients in clinical transition from skin to joint disease: a randomized clinical trial.
This clinical trial is investigating a new approach to psoriatic arthritis (PsA). PsA can cause joint pain and inflammation, and this study aims to catch it early, before it fully takes hold. Researchers are testing a medicine called Guselkumab to see if it can prevent or reduce the development of joint problems in people who are showing early warning signs of PsA, even if they don't have a full diagnosis yet. They are comparing Guselkumab with another established medicine, Ciclosporin. The main goal is to find out if Guselkumab can stop joint pain and inflammation, as well as improve skin symptoms and overall quality of life, in people who are at a high risk of developing PsA. This is a Phase IV study, meaning the medicine is already approved for some uses, but researchers are looking at new ways it can help.
En un coup d'œil
De quoi parle cette étude ?
When people have psoriasis, a skin condition, they sometimes develop psoriatic arthritis (PsA), which affects the joints. This study is like a detective story, trying to catch PsA very early, before it becomes a big problem. The researchers are focusing on people who have psoriasis and are starting to show some signs of joint pain, but haven't been fully diagnosed with PsA yet. This early stage is called 'subclinical psoriatic arthritis' or 'clinical transition' from skin to joint disease. Think of it as a warning sign that PsA might be on its way.
The main aim of this research is to see if a medicine called Guselkumab can stop or significantly slow down the development of PsA in these high-risk individuals. Guselkumab is already used for some conditions, and this study explores if it can be an 'interception' treatment – meaning it steps in early to change the course of the disease. They are comparing it to another drug, Ciclosporin, which is also used in certain inflammatory conditions.
The researchers will be carefully looking at whether Guselkumab can get rid of joint pain and inflammation effectively. They will also be checking if it helps with skin problems, improves day-to-day life, and prevents further joint damage over time. By finding treatments that can work early, the hope is to prevent people from experiencing the full impact of psoriatic arthritis.
Points clés
- This study aims to prevent psoriatic arthritis in its very early stages.
- It tests a medicine called Guselkumab against Ciclosporin.
- Participants will have early joint pain and psoriasis, but not a full PsA diagnosis.
- The study lasts about a year and involves regular checks and medication.
- The goal is to stop joint inflammation and pain before it becomes severe.
Qui peut être éligible ?
To be considered for this study, participants must be at least 18 years old. Both men and women are welcome to take part.
The study is specifically looking for people who have psoriasis and are starting to experience some joint pain or discomfort, but haven't been officially diagnosed with psoriatic arthritis yet. This means you might have skin symptoms of psoriasis and early indications that your joints could be affected.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Avez-vous 18 ans ou plus ?
- Do you have psoriasis (a skin condition)?
- Are you experiencing some joint pain or discomfort?
- Have you NOT yet been officially diagnosed with psoriatic arthritis?
- Are you generally able to attend regular appointments for about a year?
En quoi consiste la participation ?
If you decide to take part in this study, you would receive either Guselkumab or Ciclosporin. Guselkumab is given as an injection using a pre-filled syringe. You'll have regular appointments over roughly a year to check how you're feeling and how the medication is working. These appointments will involve tests to measure any pain or inflammation in your joints, and potentially ultrasound scans to get a closer look at your joints. Researchers will also ask about your skin symptoms and how your condition affects your daily life. The total duration of your active participation, including medication and assessments, would be about 52 weeks (one year).
Risques et avantages potentiels
Emplacements (1)
- —Non vérifiéItalie
Questions fréquentes
What is 'subclinical psoriatic arthritis'?
It means you have early signs of psoriatic arthritis, like joint pain, but you don't officially meet all the criteria for a full diagnosis yet.
What is Guselkumab?
It's a medicine given by injection that targets specific parts of the immune system involved in inflammation. It's already approved for some conditions, and this study explores its use for early PsA.
What is Ciclosporin?
Ciclosporin is another medication that works by calming down the immune system. It's used in various inflammatory conditions.
How long will the study last if I join?
Your active participation in the study, including treatment and follow-up, would be for about one year (52 weeks).
Will I get paid to be in the study?
The study information provided doesn't mention payment for participants. You should ask the study team about any potential reimbursements for travel or expenses.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.